Oncology Leads Personalized Medicine

Article

Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-06-01-2015
Volume 24
Issue 6

Study finds that almost 75% of cancer drug candidates rely on biomarker data. 

 

The opportunity to more precisely target and to personalize medical treatments based on biomarker data has attracted growing interest from biopharmaceutical companies. A recent study by the Tufts Center for the Study of Drug

Number of compounds in R&D that rely on biomarker data.

Development (Tufts CSDD) finds that oncology dominates personalized medicine product development in part because cancer-related illnesses are extremely complex and they receive the highest level of R&D activity. Companies involved in developing personalized medicines report that across all phases, 73% of oncology drugs now rely on biomarker data. This compares with 42% of compounds in all indications.

- Tufts CSDD 

 

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.